ophthalmology

Eye diseases and vision: drugs for retinal disease, lenses and eye-care devices.

Theme · 5 companies · 0 report it as a revenue line

Show
8-K events
Match any selected event
8-K event types
More events

Only filters 8-Ks. Other selected forms stay visible.

Role
  • ABBV AbbVie

    Sells it“AbbVie’s eye care products address unmet needs and new approaches to help preserve and protect patients’ vision.”

    Latest 10-QQ3 FY2026Positive ·

    Skyrizi and Rinvoq more than offset Humira erosion; lower acquired R&D and impairment charges amplify the earnings rebound.

    • Revenue$17.4BYoY +10.3%
    • Net income$4.2Bvs $186.0M year ago
  • ADRX ADARx Pharmaceuticals, Inc.

    In development“In November 2025, we initiated a Phase 2 randomized, masked, placebo-controlled clinical trial of SC administered agazisiran in participants with GA secondary to AMD.”

    Latest 424B4final IPO prospectusPositivePre-revenue ·

    Develops siRNA drugs for hereditary angioedema and other diseases; $446M all-primary raise funds clinical development

  • CTY CITY THERAPEUTICS, INC.

    In development“CITY-RBP4 is a City-engineered GalNAc-conjugated siRNA therapeutic candidate designed to target RBP4 mRNA for the treatment of retinal diseases characterized by the toxic accumulation of vitamin A byproducts.”

    Latest 424B4final IPO prospectusCustomer concentration ·

    Develops RNA interference drugs led by CITY-FXI for thrombosis; raises $200M entirely through new shares.

  • JNJ Johnson & Johnson

    Sells it“The Vision portfolio includes contact lenses marketed under the ACUVUE brand, TECNIS premium intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures.”

    Latest 10-QQ3 FY2026MixedRestructuringImpairment / chargeLegal / investigation ·

    TREMFYA and oncology growth offset STELARA’s biosimilar erosion, but a proposed talc-settlement charge nearly wiped out earnings.

    • Revenue$25.4BYoY +5.9%
    • Net income$210.0MYoY −95.9%
  • REGN Regeneron Pharmaceuticals

    Sells it“EYLEA HD received U.S. approval for dosing intervals up to 20 weeks in wet AMD and diabetic macular edema.”

    Latest 10-QQ3 FY2026Positive ·

    Dupixent growth and richer Sanofi profit sharing more than offset EYLEA erosion, deepening reliance on the partnership.

    • Revenue$5.1BYoY +36.3%
    • Net income$1.9BYoY +33.5%

Feedback